You are on page 1of 5

EAAHNIKH L\HMOKPATIA

AS~va ~3rJ(~t2

npOe; roue . An: l8\


krrpucouc ~uMoyoue; rnc Xwpae;

Kupla/E npOEOpE,

~ae;ola~l~a~ouIlE Eyypacj>o rou ESVlKOU Opyavlollou napox~e; YRI1PEOlWVYYElae;,


rEV.f!.jvOI1 OpyavWOI1e; & ~XEOLUOIlOU
Ayopae; YRI1PEOlWVYydae;, f!.jvol1 CDapllaKou, TIl~lla
~XEolaollou KaL napaKoAoUSl1011e; Xop~Yl1ol1e;CDapllaKwv, aplSIl·RPWT. 2308/18.1.2018, (An
nI~: 173/22.1.2018), IlE SElla: «~XETlKa IlE cj>apllaKa ROU E~ETa~OVTaL
aRO ne; EmTpOREe;ROU
E~Ha~oVTal aRO nc; EmTpoREC;<DapllaKwv xm YtlJllAou Koorouc», IlE Til
E~WTEPlKOU
RapaKAIlOIl ORWC;EVIlIlEPWOETE ru IlEAI1 REPlOX~C;EUSUVIle;TOU ~uMovou oae;.

IlANEAAHNIO!: IAT PIKO!: !:Y AAoro!: (Il.I.!:.)


TIAOYTAPXOY 3 & Y\f'HAANTOY. 10675 A8HNA. THA.: 210 7258660, 2107258661,2107258662, FAX: 210 7258663
PANHELLENIC MEDICAL ASSOCIATION. 3, PLOUTARCHOU & IPSILANDOU Str., 10675 ATHENS. HELLAS
www.pis.gr e e-mails:KENTPIKO:pisinfo@pis.gr.rPAMMATEIA:pis@pis.gr.I1PQTOKOAAO:pisref@pis.gr
AOrILTHPIO: pislog@pis.gr • ME8NEL: pisinter@pis.gr, pisinterl@pis.gr
MHXANOrPA<l>HLH:pismember@pis.gr
MA: 63XZO=:7M-44JZ
INFORMATICS P,,~~M~by
DE VEL 0 P MEN DEVELOPMENT AGENCY
T AGENCY ~~~'2018.0122""8,3.
Reason:
location: Athens

EAAHNJKH ~HMOKPATIA
A9~va, 18-01-2018
VIlOyprEIO VrElAI:
Ap. npWT.: o1K.2308
EeVtKOC;

lut
EOnVV
Opvcvtouo;
napoX11C;
Ymtpscuov
Yy£i.ac;
www.eopyy.gov.gr

r£VIK~ ll./vorJ: OPyovworJC; & IX£~laolJou npOI:


AyopoC; YnrJp£oloov Yy£iac; i.ns.zr sonvv cnEpl<pEpElaK£C;
ll./vorJ: cJ)apIJOKOU nlEU8uvaEIC;EOnyy)
TIJ~lJa: IX£~laolJou Kal napaKoAou9rJorJC; 2.AnoKEVTpWIJ£Var porpsio
XOP~YrJorJC; cJ)apIJOKWV E~Unl1p£Tl1al1C;
Aa<paA1alJ£vWVEOnyy
nArJPoq>opi£C;: X.Kav~ 3.YYEIOVOIJ1K£C;
nEpl<p£pEIEC;,
ynE
TI1A.:210 8110655, 575 Fax:210 8110544 4. LTPOTIWTIKONOaOKOIJEia
Tax. !1/val1: An.Ilouxou 12, T.K. 151 23 Mapoum 5.navEM~vlo IOTPIKOLuMoyo
E-mail: d6.t1@eopyy.gov.gr 6.navEM~vlo <l>aplJaKEUTIKoLuMoyo

KOINonOIHIH:
t.rpooelo Ynoupvou YYEiac;
2.rpa<pEio Av.Ynoupvou Yvsloc
3. Fporpelo rEV.rpaIJIJOT£WC;
nl1lJomac;
nlOiKl1al1C;
4.!1/val1 Aa<paAlalJ£VWvEOnyy
5. rpa<pEio npo£opou sonvv
6. rpooelo AVTlnPO£Opousonvv
7. rpoodo rEV. !1/VTI1
8. oooucselo sonvv
9.HnlKA
10.ynEn Y<l>KA
1loKMEL

0ElJa: «IXETIKO IJE q>oPlJaKa nou E~ETo~oVTal ana TIC;EnlTpOnEC; <l>apIJOKWV E~WTEPIKOU
Kal V'PIlAou KOOTOUC;».
IXETIKO: 1. 01 Y.A. L\3(a)/77022/31.10.2017 (<l>EKB' 3823) «n L\3(a)/87526 /20.12.2017 (<l>EKB'
4506) 8HIKOC; KOTOAOY0C;LUVTayoypa<pOlJI-lEVWVoopuoxcov
2. To I-lE ap. nper. oIK.27463/29.06.2017 (AM: QTITO=:7M-<l>Xn) tyypmpo <J)(ETIKOI-lE cpoPl-laKa
nou E~ETo~oVTalana TIC;EniTpontc; oopuuxrov E~WTEPIKOU«n YljJrjAOU KOOTOUC;
3. H Y.A. 3457/16.01.2014 (<l>EKB' 64) ap.ll napA
4. To un ' ap. nporr. L\B4Ajr32joIK.8774j01.03.2017 (op8~ EnaVOArjljJrj 15.03.2017) tyvpacpo
<J)(ETIKOI-lEnapaAa~~ OrjI-lEIWI-l0TWVEnITpOnWv
5. To un ' ap. nporr. L\B4Ajr32/oIK.12075/17.03.2017 tyypacpo <J)(ETIKO I-lE KaT68Eor]
OIKOIOAOYrjTIKWVOTIC;Enrrponsc <l>apl-lOKwVE~WTEPIKOUKOIYljJrjAOU KOOTOUC;EOnyy.
6. To un ' ap. nporr. L\B4Nr31/6/oIK.1267/04.01.2017 tyypacpo ovooopnca I-lE OOrjyiEC;AEIToupyiac;
rpal-ll-laTEiac; Enrrporuov <l>apl-l0Kwv E~WTEPIKOU«n YljJrjAOU KOOTOUC;

LEAtoa1 ana 4
AbA: 63XZO:=:7M-44'Z

7. To un ' ap. nperr LlB4A /f99/oIK.18880/05.05.2017 CALlA: 6Y400=7M-=Ln) Evvpacpo OXETIKO


~E cnooroxn ormucrtov Via EVKPIOIl copucxcov ~EOW IlAEKTPOVIKOUroxuopopeiou OTIe:;Enrrponec
<t>ap~oKwv YlJ.iIlAOUKOOTOUe:;EOnyy
8. To un ' ap. nporr. f32/0IK. 35621/24-08-2017 Cop8~ maVOAIllJ.i1l 27-09-2017) Evvpacpo OXETIKO
~E nporuno VVW~OTEUOIle:;nou oeopo OE ocp8aA~oAoVIKO cpop~aKa

LE OUVEXElaTile:; EKOOOIle:;TWV 8ETIKWV Kcroxovcov LUVTavovpacpOU~EVWV <t>ap~OKWVCOXETIKO


1) Kal ~E ~OOIl TIe:;OlaTO~EIC;Tile:;YnoupVIK~C; Anoooonc 3457/16.01.2014 COXETIKO3) rn cpop~aKa
nou 8a E~ETo~oVTal 01 npoOn08EoEIC; XOP~VIlOIlC; TOUC;Kal ceopouv OE EKTEAEOIl ouvrovov OTa
copuoxsio TOU opvoviouou 8a slvo: rc KOTW81:

A/A EMnOPIKH ONOMAIIA 4PAITIKH OVIIA


1 ALDURAZYME LARONIDASE
2 BENLYSTA BELIMUMAB
3 BLINCYTO BLINATUMOMAB
4 BOTOX BOTULINUM TOXIN TYPE A
5 CAPRELSA VANDETANIB
6 CEHADO ALITRETINOIN
7 CERDELGA ELIGLUSTAT
8 CEREZYME IMIGLUCERASE
9 COTELLIC COBIMETINIB
10 CYRAMZA RAMUCIRUMAB
11 DAKLINZA DACLATASVIR
12 DYSPORT BOTULINUM TYPE A TOXIN HAEMAGLUTININ COMPLEX
13 ELAPRASE IDURSULFASE
14 EPCLUSA VELPATASVIR:SOFOSBUVIR
15 ERIVEDGE VISMODEGIB
16 ESBRIET PIRFENIDONE
17 EXVIERA DASABUVIR
18 EYLEA AFLIBERCEPT
19 FABRAZYME AGALSIDASE BETA
20 FORSTEO TERIPARATIDE
21 HARVONI SOFOSBUVIR, LEDIPASVIR
22 ILARIS CANAKINUMAB
23 IMBRUVICA IBRUTINIB
24 JAKAVI RUXOLmNIB
25 JETREA OCRIPLASMIN
26 KEYTRUDA PEMBROLIZUMAB
27 KUVAN SAPROPTERIN DIHYDROCHLORIDE
28 LENVIMA LENVATINIB MESILATE
29 LUCENTIS RANIBIZUMAB
30 LYNPARZA OLAPARIB
31 MACUGEN PEGAPTANIB SODIUM
32 MEKINIST TRAMETINIB
33 MYOZYME ALGLUCOSIDASE ALFA
34 NEUROBLOC BOTULINUM TOXIN TYPE B

LEAloa2 ana 4
35 OFEV NINTEDANIB
36 OLYSIO SIMEPREVIR
37 OPDIVO NIVOLUMAB
38 OZURDEX DEXAMETHAZONE
39 PRALUENT ALIROCUMAB
40 RAXONE IDEBENONE
41 REMODULIN TREPROSTINIL
42 REPATHA EVOLOCUMAB
43 REPLAGAL AGALSIDASE ALFA
44 SOVALDI SOFOSBUVIR
45 SPINRAZA NUSINERSEN
46 SYLVANT SILTUXIMAB
47 SYNAGIS PALIVIZUMAB
48 TAFINLAR DABRAFENIB
49 TAGRISSO OSIMERTINIB
50 VENCLYXTO VENETOCLAX
51 VICTRELIS BOCEPREVIR
52 VIEKIRAX RITONAVIR1 PARITAPREVIR1 OMBITASVIR
53 VISUDYNE VERTEPORFIN
54 VPRIV VELAGLUCERASE ALFA
55 XOFIGO RADIUM (223RA) DICHLORIDE
56 XTANDI ENZALUTAMIDE
57 YERVOY IPILIMUMAB
58 ZAVESCA MIGLUSTAT
59 ZELBORAF VEMURAFENIB
60 ZEPATIER GRAZOPREVIR: ELBASVIR
61 ZYDELIG IDELALISIB
62 ZYTIGA ABIRATERONE

Eruonpoivero: OTI TO CPOPI-lOKOYIO TI'lV I'lnOTiTIOO C TOU OV(J)T£PW nlvoxo 80 E~OKoAou8~aouv va


E~ETO~OVTOIana TI'lV EniTpOn~ CDOPI-l0KWVE~WTEPIKOU KOI Y4JI'lAou KOOTOU<;A8~vo<;.

Enial'l<; TO SPINRAZA 80 E~ETO~ETOI ana TI'lV Enrrponn CDOPI-l0KWV E~WTEPIKOU KOI Y4JIlAou
KOOTOU<;TIl<; A8~voc;.

Eninpoa8ETO{ E~ETO~OVTOI ana TI'lV Erurponri CDOPI-lOKWVE~WTEPIKOU KOI Y4JI'lAou KOOTOUC;TI'l<;


A8~vo<; TO POOIOCPOPI-lOKO{CPOPI-lOKOE~WTEPIKOU nou ooopouv aE OTOI-lIK£<;ncpovvexlec ~ £KTOKTE<;
EleJOYWY£<;KOI coo coopouv OTI<; OIOTO~EIe;rnc Y.A. 82961 (CDEK 2219 B1/09.09.2013) <J)(ETIKOI-lE
ono~l'll-liwal'l CPOPI-l0KWV nou srcovovrcn I-lE EKTOKTEe;OloolKoaiEe; ana TOV EOCD KOI TO ICDET EWe;TIlV
OPIOTIK~ o~loMYllal'l TOUe; ana TIlV oPI-l60IO EnITpOn~ ~ Til M~1l Tile; EVOEOEIYI-lEVIle; nEplOOOU
8EponEioe;.

01 nEpInTCDOEIe;nou E~ETO~OVTOI ana TIe; Enrrponec CDOPI-l0KWV E~WTEPIKOU KOI Y4JI'lAou KOOTOUe;
unopouv va rpononomaouv I-lE onoeoon TOU npOEOpOU TOU OPYOVI0I-l0U.
LEAtoa 3 cno 4
MA: 63XZO:::7M-44JZ

Eruonpoivertn OTI 01 aVWTEpW anrrponcc OEV eivci EK TOU VOI.I0U apI.IOOIEe;va E~ETa~ouv
nEpInTCiJOEIe;EKTOe;EVOEi~EWVouvrovovooononc ouuqxovo I.IE rnv Ynoupvucq onocoon LWr3a/0IK.
r.Y. 154/29-02-2012 (cDEK 545/8' /01-03-2012) 11onoia KOlvOnOI~8IlKE I.IE TO 16217/09-04-2012
Eyypa<po Tile; Ynnpeoloc ucc, ouuqxovo I.IETIlV onoia opuooro elvoi EIOIK~ Enrrponn TOU EOcD.

o npOEl1POI eonvv

lfiTHPIOI MnEPIIMHI
En. KaerlYIlT~C;naVWrOTIlIJiOUnErparwc;

LEAtoa 4 uno 4